Paid Clinical Trials Oklahoma
Discover 832 paid clinical trials in Oklahoma. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
P-CD19CD20-ALLO1P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Sponsor:
Poseida Therapeutics, Inc.
Location:
Code:
NCT06014762
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High-grade B-cell Lymphoma
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Transformed Follicular Lymphoma (tFL)
Follicular Lymphoma Grade 3B
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
P-CD19CD20-ALLO1
Rimiducid
Observational StudyContinuous Monitoring and Control of Hypoglycemia
Sponsor:
DexCom, Inc.
Location:
Code:
NCT03340831
Conditions
Diabetes
Eligibility Criteria
Sex: All
Age: 2+
Healthy Volunteers: Not accepted
Interventions
Continuous Glucose Monitoring (CGM)
NX-1607A Study of NX-1607 in Adults With Advanced Malignancies
Sponsor:
Nurix Therapeutics, Inc.
Location:
Code:
NCT05107674
Conditions
Ovarian Cancer, Epithelial
Gastric Cancer
GastroEsophageal Junction (GEJ) Cancer
Head and Neck Squamous Cell Carcinoma
Metastatic or Unresectable Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
NX-1607
Paclitaxel
Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
EtrasimodAn Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
Sponsor:
Pfizer
Location:
Code:
NCT06398626
Conditions
Colitis, Ulcerative
Eligibility Criteria
Sex: All
Age: 18 - 64
Healthy Volunteers: Not accepted
Interventions
Etrasimod
Exoskeleton-Assisted Gait TrainingEffects of Exoskeleton-Assisted Gait Training on Functional Rehabilitation Outcomes in Patients With Stroke
Sponsor:
University of Oklahoma
Location:
Code:
NCT03980457
Conditions
Stroke
Weakness of Extremities as Sequela of Stroke
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Indego Exoskeleton
Standard Rehabilitation
Lenalidomide & DaratumumabS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT04071457
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Lenalidomide
Daratumumab/rHuPH20
CariprazineA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Sponsor:
AbbVie
Location:
Code:
NCT04777357
Conditions
Depression
Bipolar I Disorder
Eligibility Criteria
Sex: All
Age: 10 - 17
Healthy Volunteers: Not accepted
Interventions
Cariprazine
Placebo
Selumetinib vs. Carboplatin/VincristineA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate
SeralutinibEfficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Sponsor:
GB002, Inc.
Location:
Code:
NCT05934526
Conditions
Pulmonary Arterial Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo
Seralutinib
Generic Dry Powder Inhaler